0ME Stock Chart & Stats
€50.00
-€2.52(-5.45%)
At close: 4:00 PM EST
€50.00
-€2.52(-5.45%)
Day’s Range― - ―
52-Week Range€20.36 - €90.00
Previous CloseN/A
Volume0.00
Average Volume (3M)44.00
Market Cap
€5.40B
Enterprise Value€5.13B
Total Cash (Recent Filing)€171.67M
Total Debt (Recent Filing)€95.84M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Jul 31, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding62,271,313
10 Day Avg. Volume43
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€76.88Price Target Upside53.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.82
Revenue Forecast (FY)€391.84M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue Growth & Clear Path To BreakevenThirteen consecutive quarters of sequential revenue growth and raised FY26 guidance indicate durable product adoption and expanding customer traction. A management‑stated path to adjusted‑EBITDA breakeven provides a concrete execution milestone that if hit materially reduces financing risk and supports sustainable operating discipline.
Sustained Gross Margin ExpansionMargin expansion above 50% reflects favorable product mix, manufacturing leverage, and higher-value NGS/therapeutics sales. Management cites strong incremental gross‑margin drop‑through on new revenue, implying new sales more directly boost profitability and enabling durable operating leverage as volumes scale.
Strategic Partnerships & Therapeutics TractionPartnerships with large ecosystem players and licensing wins expand addressable market and create sticky commercial channels. Rapid therapeutics growth shows adoption by biopharma customers, supporting higher‑margin, recurring program work and strengthening long‑term revenue mix toward commercial discovery customers.
Bears Say
Ongoing Cash BurnNegative operating and free cash flow indicate the business still requires external capital until adjusted‑EBITDA breakeven is reached. Near‑term uses (CapEx, licenses, settlements) have reduced cash balances, leaving limited runway buffer that can pressure strategic flexibility or require financing if execution slips.
Persistent Profitability DeficitDespite revenue scale and margin improvement, operating losses remain sizable and return on equity is negative. Sustained unprofitability limits retained earnings to fund growth, risks further dilution or debt if expansion continues, and makes achievement of the breakeven target critical for long‑term viability.
End‑Market Headwinds & Acceptance GapsReliance on markets facing secular funding pressure (academic/government) and manufacturing acceptance failures that drive customers elsewhere create structural demand and retention risks. Addressing acceptance rates and diversifying end markets are required to sustain revenue durability and avoid recurring lost orders.
Twist Bioscience News
0ME FAQ
What was Twist Bioscience’s price range in the past 12 months?
Twist Bioscience lowest stock price was €20.36 and its highest was €90.00 in the past 12 months.
What is Twist Bioscience’s market cap?
Twist Bioscience’s market cap is €5.40B.
When is Twist Bioscience’s upcoming earnings report date?
Twist Bioscience’s upcoming earnings report date is Jul 31, 2026 which is in 23 days.
How were Twist Bioscience’s earnings last quarter?
Twist Bioscience released its earnings results on May 04, 2026. The company reported -€0.62 earnings per share for the quarter, missing the consensus estimate of -€0.417 by -€0.204.
Is Twist Bioscience overvalued?
According to Wall Street analysts Twist Bioscience’s price is currently Undervalued.
Does Twist Bioscience pay dividends?
Twist Bioscience does not currently pay dividends.
What is Twist Bioscience’s EPS estimate?
Twist Bioscience’s EPS estimate is -0.43.
How many shares outstanding does Twist Bioscience have?
Twist Bioscience has 62,271,313 shares outstanding.
What happened to Twist Bioscience’s price movement after its last earnings report?
Twist Bioscience reported an EPS of -€0.62 in its last earnings report, missing expectations of -€0.417. Following the earnings report the stock price went up 1.073%.
Which hedge fund is a major shareholder of Twist Bioscience?
Currently, no hedge funds are holding shares in DE:0ME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€76.88 (53.77% Upside)
€76.88 (53.77% Upside)
Blogger Sentiment
Neutral
DE:0ME Sentiment 50%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth €2.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
161.80%
12-Months-Change
Fundamentals
Return on Equity
-17.46%
Trailing 12-Months
Asset Growth
13.53%
Trailing 12-Months
Company Description
Twist Bioscience
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
0ME Company Deck
0ME Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and commercial story: strong top-line growth (19% YoY), robust outperformance in therapeutics (55% YoY), gross margin above 50%, strategic partnerships (AWS) and an explicit path to adjusted EBITDA breakeven in Q4 FY2026. Offsetting these positives are ongoing adjusted EBITDA losses, higher operating expenses tied to strategic investments, a reduction in cash balances, a pending litigation settlement and certain end-market pressures (academic funding headwinds and some segment declines). Management provided clear remediation steps (cost reductions, targeted automation, acceptance-rate improvements) and raised full-year guidance, indicating confidence in execution.View all DE:0ME earnings summaries0ME Stock 12 Month Forecast
Average Price Target
€76.88
▲(53.77% Upside)
Technical Analysis
Options Prices
Currently, No data available
---